title: Intravitreal Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion in Chinese Patients.
abstract: OBJECTIVE
  To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients from Taiwan, China, with macular edema secondary to branch retinal vein occlusion (BRVO).
  
  
  METHODS
  A total of 32 patients with macular edema associated with BRVO, without prior macular laser or other intervention, were enrolled consecutively from September 2013 to February 2015. The cases received single 2 mg injections of intravitreal aflibercept. Primary outcome measures included changes in central foveal thickness (CFT; 1 mm increments by spectral-domain optic coherence tomography) and best corrected visual acuity (BCVA), determined at 1, 2, and 3 months after the injection. Complications after injections were recorded. The changes in CFT and BCVA were compared with Wilcoxon sign-rank tests.
  
  
  RESULTS
  The CFT was significantly reduced and the BCVA was significantly improved at 1, 2, and 3 months after injection (all P < 0.05). Tomography findings revealed no recurrence within 3 months. No systemic thromboembolic events, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis occurred following injection.
  
  
  CONCLUSIONS
  Single intravitreal aflibercept may be useful in treating macular edema associated with BRVO within 3 months. No adverse systemic or ocular effects were found in this case series.
authors.forename: Jia-Kang
authors.initials: JK
authors.lastname: Wang
authors.forename: Tzu-Lun
authors.initials: TL
authors.lastname: Huang
authors.forename: Pei-Yuan
authors.initials: PY
authors.lastname: Su
authors.forename: Pei-Yao
authors.initials: PY
authors.lastname: Chang
authors.forename: Ying-Yu
authors.initials: YY
authors.lastname: Tseng
mesh_terms: D044466:Asian People; D009877:Endophthalmitis; D005584:Fovea Centralis / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012163:Retinal Detachment; D012170:Retinal Vein Occlusion / Q000150:complications*; D013624:Taiwan; D014792:Visual Acuity
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor